Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07608718 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 2 study, sponsored by Pedro Barata, MD, MSc.
- Not yet
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT07608718: Clinical Trial Phase 2 study, sponsored by Pedro Barata, MD, MSc.
NCT07608718 is a Phase 2 study that has not yet begun recruiting, run by Pedro Barata, MD, MSc. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07608718, a Phase 2 study, has not yet begun recruiting, sponsored by Pedro Barata, MD, MSc.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior treatment. Participants can stay in the research for up to 24 months as long as they experience clinical benefit from it. The purpose of this study is to learn if Zanzalinitib is effective in treating metastatic castrate-resistant prostate cancer.
Primary Outcome
rPFS is defined as the duration of time from start of treatment to time of progression
Interventions
- DRUG Zanzalintinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2026-09 |
| Est. Completion | 2030-05 |
| Phase | Phase 2 |
What is known before NCT07608718 opens enrollment
NCT07608718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Zanzalintinib is the first listed.
NCT07608718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07608718 about?
NCT07608718 is a clinical study titled "Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer". This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior treatment. Participants can stay in the research for up to 24 months as long as ...
What is the current status of trial NCT07608718?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2026-09. Estimated completion is 2030-05.
What interventions are being tested in trial NCT07608718?
The interventions under investigation include: Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT07608718?
This trial is sponsored by Pedro Barata, MD, MSc, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07608718's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia